I
t has been reported that approximately one-third of constipation patients in tertiary care centers have dyssynergic defecation, [1] [2] [3] and up to 82% of chronic constipation patients fulfill the criteria for irritable bowel syndrome (IBS). 3 Symptoms of dyssynergic defecation such as incomplete evacuation and excessive straining are also common in patients with IBS. 4, 5 It has been reported that symptoms of incomplete evacuation are associated with rectal hypersensitivity in IBS. 6 The primary symptoms of IBS are abdominal bloating and abdominal pain/discomfort, which are usually improved by successful bowel evacuations. 7 It is conceivable that increasing the chances of successful bowel movements in dyssynergic constipation patients with IBS symptoms by biofeedback therapy may improve not only the constipation symptoms but also the concomitant IBS symptoms. In contrast, the presence of incomplete evacuation and rectal hypersensitivity in IBS may adversely affect the outcome of biofeedback therapy in dyssynergic defecation with IBS if the rectal hypersensitivity is not corrected.
Biofeedback therapy using the manometric technique has been reported to be an effective treatment for dyssynergic defecation. 8 Chiarioni et al 9 reported a long-term improvement of bloating symptoms after biofeedback therapy in chronic constipation patients. That study suggested that biofeedback therapy might improve both constipation and abdominal bloating/discomfort in patients suffering from both anorectal dyssynergia and IBS. However, according to the Rome II and III criteria, 10, 11 patients with coexisting dyssynergic defecation and IBS have to be excluded before the diagnosis of dyssynergic defecation. If the presence of IBS in dyssynergic defecation does not affect the outcome of the biofeedback therapy, the Rome criteria may mislead physicians and prevent many patients who suffer from both IBS and dyssynergic defecation from receiving the benefit of biofeedback therapy. In contrast, if the presence of IBS adversely affects the treatment outcome excluding constipation patients with IBS from the anorectal physiologic tests and biofeedback therapy will save the management cost in this patient group. Therefore, the primary aim of this study was to determine whether the presence of IBS in patients with dyssynergic defecation adversely affects the outcome of biofeedback therapy. The secondary aims were as follows: (1) to determine whether the improvement of defecation indices in patients with dyssynergic defecation is associated with the improvement of IBS symptoms and (2) to determine the patient factor(s) that is associated with the biofeedback treatment outcome.
MATERIALS AND METHODS

Patients
We recruited consecutive patients with functional constipation as defined by the Rome II criteria 7 (1) the presence of a dyssynergic or obstructive pattern of defecation, which was defined as a paradoxical increase in anal sphincter pressure or <20% relaxation of the resting anal sphincter during attempted defecations or strainings, (2) an impaired defecation index, which was defined as rectal pressure values divided by anal residual pressure during straining of <1.2, and (3) an inability to expel a 50 mL water-filled balloon within 3 minutes.
Patients who presented the following were excluded from the study: (1) serious concomitant psychiatric problems such as psychosis and major depression; (2) neurological disorders including cerebrovascular disease, Parkinson disease, and cognitive impairment; (3) visual or hearing problems; (4) an inability to terminate the use of medications that may cause constipation; (5) refusal to receive the biofeedback therapy; or (6) pregnancy. All of the patients were required to have a negative double-contrast barium enema or a negative colonoscopy within the previous year before inclusion in the study.
All of the patients provided written informed consent before inclusion in the study. The study was approved by the institutional review board of the Faculty of Medicine, Chulalongkorn University.
Anorectal Manometry, Balloon Expulsion Test, and Colonic Transit Test
The water perfused anorectal manometry [Polygram Net (TM), Medtronic Inc, Minneapolis, MN], balloon expulsion test, and colonic transit test were performed as described previously.
2 Defecation dynamics were studied while the manometric catheter side holes were located at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0 cm from the anal verge (Zinetics AMC Anorectal Catheter, Medtronic, Inc, Saltlake city, UT). The patients were asked to squeeze the anal sphincter as hard as possible 3 times for 15 seconds each, followed by straining equivalent to that performed during a bowel movement at home again repeated 3 times for 15 seconds each. There was a 30 seconds rest period between each squeezing and straining. The balloon was then inflated manually to 10, 20, 30, 40, 60, 80, 100, and 120 mL to evaluate the rectoanal inhibitory reflex and rectal sensation. 2 Patients were provided a standardized verbal explanation of the sensory scales at the start of the study and were asked to report the occurrence of rectal sensation (1, first sensation; 2, first sensation of urgency of stool; and 3, first sensation of intolerable need to pass stool) and pain (1, first sensation of pain; 2, moderate pain; and 3, severe pain) during each rectal balloon distention.
The balloon expulsion test was performed using a nasogastric tube with a 3 cm long latex balloon, which was filled with 50 mL water after insertion into the rectum. 13 The patient was asked to sit on a commode and to expel the balloon in privacy. The balloon expulsion time was recorded. If the patient failed to expel the balloon within 5 minutes, the balloon was deflated and removed. 2 Colonic transit was measured using 20 solid radiopaque markers in a gelatin capsule. 2 The makers were prepared by cutting 5 F angiogram catheters to cylindrical shapes (1.67Â6 mm) [Angiographic Catheter (IMAGER II), Boston Scientific Corporation, Natick, MA]. A delayed colonic transit was defined as Z20% (Z4 markers) retention of the markers on day 5, as visualized by plain abdominal radiographic image(s). 14 
Biofeedback Protocol
All of the patients who fulfilled the inclusion criteria were informed about their physiological abnormalities underlying the constipation and the objectives of the biofeedback therapy 2 weeks before the initiation of therapy. All of the patients were asked to visit the GI Motility Research Unit, King Chulalongkorn Memorial Hospital, Bangkok, for biofeedback therapy once a week for 4 consecutive weeks.
Each biofeedback session consisted of visual and verbal feedback techniques using a solid state anorectal manometry catheter with 4 solid state sensors located 0, 1, 2, and 5 cm from the anal verge (Unisensor AG, Bahnstrasse 12 a, CH-8544 Attikon, Switzerland). The manometry data collected during the biofeedback therapy were recorded using a commercially available manometric system (Polygram Net, Medtronic Inc, Minneapolis, MN) for later analysis. Visual feedback was provided by observing the changes in pressure on the monitor screen. Verbal feedback was provided by a physician and a nurse therapist. The therapists were not aware of patients' IBS status. Patients were asked to bear down several times (mimicking defecation) and to observe the pattern of defecation on the monitor. Each session lasted 45 to 60 minutes. The purpose of the therapy was to establish a normal pattern of straining 15 that consisted of a rise in rectal pressure synchronized with anal relaxation and a breathing technique to improve the pushing effort during defecation. All of the patients were instructed in performing a diaphragmatic breathing exercise at home during the treatment period, as described previously. 12 Rectal sensory training was not performed, because we planned to determine the role of an improvement of the defecation index in IBS symptoms.
Evaluation of Constipation, IBS, and Other Gastrointestinal Symptoms
During the biofeedback therapy and 4-week follow-up period, the patients were advised to use laxatives only when they experienced uncomfortable symptoms. Medications for IBS, including antispasmodics, tegaserod, and antidepressants, were prohibited during the study period. The stool frequency and the amounts and types of laxative consumed were recorded. Primary IBS symptoms (abdominal bloating and abdominal discomfort/pain associated with bowel movements) and other gastrointestinal symptoms, including early satiety, anorexia, nausea, and heartburn, were evaluated immediately before the first biofeedback session and 4 weeks after the end of the biofeedback therapy using a 4-point Likert scale: 0=no symptoms, 1= mild symptoms, 2=moderate symptoms, and 3=severe symptoms. 16 Constipation symptoms were evaluated using a 10 cm long visual analog scale before and 4 weeks after the end of the treatment. Biofeedback therapy was discontinued after the fourth session or when the patients reported normal bowel movements without the use of laxative and digital maneuvers for facilitation.
The definitions of successful and unsuccessful treatment were predefined. A successful treatment was defined as an improvement of at least 50% in the constipation symptom score, and unsuccessful treatment was defined as an improvement of <50% in constipation symptoms, which were evaluated 4 weeks after the end of the biofeedback treatments.
Assessment of Defecation Indices
The defecation index at baseline and the end of the last biofeedback therapy for each patient was evaluated by a physician who was unaware of the treatment outcome.
Statistical Analysis
The data were analyzed using SPSS software for Windows (version 11.5, SPSS Inc, Chicago, IL). The Student t test, Mann-Whitney U test, w 2 test, and Fisher exact test were used. Data are expressed as the means± SD or the medians and interquartile ranges. A P value of <0.05 was considered statistically significant.
We determined the sample size based on the assumptions that 35% of the patients with dyssynergic defecation and without IBS symptoms would not respond to biofeedback therapy and that a 2-fold increase in the nonresponse rate would be detected among patients with both dyssynergic defecation and IBS symptoms. Accordingly, a sample size of 21 patients per group was required to detect the between-group difference with 90% power at the 5% significance level, assuming that 20% of the patients would drop out of the study.
RESULTS
Fifty patients completed the biofeedback treatment protocol. None of the patients dropped out from the treatment. Number of biofeedback session per patient was 2.6±1.2. Twenty-nine patients finished the study before 4 sessions because they experienced successful treatment. The patient characteristics and anorectal physiological parameters of all patients, patients with IBS, and without IBS are shown in Table 1 . None of the patient reported abdominal pain in response to balloon distention during the anorectal manometry study which was performed before the biofeedback therapy.
Before the biofeedback therapy, 29 patients (58%) fulfilled the criteria for a diagnosis of IBS. Patients who had IBS were predominantly younger in age (P<0.05) and tended to be female (male:female=5:24 vs 9:12). Education levels and the prevalence of each constipation symptom were similar between patients with and without IBS (>0.05). The prevalence of a delayed colonic transit, pretreatment constipation scores, defecation indices, balloon expulsion times, resting pressure, squeezing pressure, and rectal sensory thresholds were similar between patients with and without IBS (P>0.05).
Factors Associated With Successful and Unsuccessful Biofeedback Treatment
Thirty patients were successfully treated with biofeedback therapy after 1 month. Table 2 shows the characteristics of the patients with successful and unsuccessful biofeedback treatments. Patients with an unsuccessful biofeedback treatment demonstrated higher pretreatment constipation symptom scores, a greater prevalence of delayed colonic transit, and higher rectal sensation thresholds for the initial sensation of intolerable urgency, as 
Effect of Biofeedback Therapy on Constipation Symptoms and Anorectal Functions
As shown in Table 3 , in the patients with successful treatments, the biofeedback therapy significantly decreased the symptoms of constipation, balloon expulsion times, and improved defecation indices (P<0.05). The prevalence of each constipation symptom was significantly decreased after biofeedback therapy compared with before biofeedback therapy (P<0.01). The use of laxatives was completely discontinued in every patient who demonstrated a successful treatment, and the use of digital maneuvers was discontinued in 10 of the 12 patients.
In the 20 patients with unsuccessful treatments, the prevalence of sensation of anal obstruction, the need for digital maneuvers to facilitate defecation, balloon expulsion times, and defecation indices were not significantly improved (P>0.05). However, the prevalence of the other constipation symptoms (straining, lumpy or hard stool, incomplete evacuation, and infrequent bowel movement), the constipation symptom score, and the frequency of laxative use were significantly reduced relative to the baseline values (P<0.05).
Effect of Biofeedback Therapy on Constipation Symptoms in Dyssynergic Constipation Patients With and Without IBS
The IBS statuses of the patients did not have a significant effect on the biofeedback treatment outcome. Figure 1 demonstrated the similar rates of successful biofeedback therapy in dyssynergic defecation patients with and without IBS (P>0.05).
After the biofeedback therapy, the IBS symptoms disappeared in 12 of the 29 patients who demonstrated IBS symptoms before the treatment. The disappearance of IBS was observed more frequently in patients who experienced a successful biofeedback therapy relative to those with an unsuccessful biofeedback therapy (P<0.05; Table 3 ). The disappearance of IBS symptoms was observed more often in patients with an improved defecation index (defined as a defecation index >1.2 or an improvement of more than 50% in the defecation index at the end of the biofeedback therapy) relative to those with no improvement of the defecation index (4 of 17 vs 8 of 12, P<0.05). The combined abdominal bloating and abdominal discomfort/ pain symptom scores in patients with an improved defecation index were significantly improved after the biofeedback therapy [before treatment 
DISCUSSION
This study demonstrated that 58% of patients with dyssynergic constipation fulfilled the Rome II criteria for IBS and the presence of IBS did not affect the treatment outcome of the biofeedback therapy. The patients with or without IBS demonstrated a similar improvement of their constipation symptoms after the biofeedback therapy. Moreover, the biofeedback therapy also improved IBS symptoms. The improvement of IBS symptoms was associated with improved dyssynergic defecation.
Our results are in agreement with previous studies that reported an improvement of abdominal pain and bloating after biofeedback therapy in patients with constipation. 9, 17, 18 Unfortunately, according to the Rome II and III criteria, dyssynergic constipation patients with IBS must be excluded before the diagnosis of dyssynergic defecation. This may mislead physicians and prevent more than half of the patients with dyssynergic defecation from receiving the proper diagnostic tests and therapy.
Several mechanisms have been proposed to explain the pathophysiology of IBS, including abnormal gastrointestinal motility and visceral hypersensitivity to chemical and mechanical stimulation. [19] [20] [21] [22] [23] In healthy volunteers, intestinal gas retention caused by an obstructed evacuation produces more abdominal pressure/bloating and abdominal cramping pain than does gas retention induced by an inhibition of intestinal motility. 24 This finding suggests that obstructed defecation plays a larger role in the development of abdominal pain and bloating symptoms than does an inhibition of intestinal contractions. The results of our study suggest that in patients with dyssynergic constipation and IBS, an obstructed evacuation of colonic contents caused by anorectal dyssynergia is associated with IBS symptoms, including abdominal bloating, discomfort, and pain.
Although several authors have recommended anorectal function tests in constipation-predominant IBS, [25] [26] [27] [28] the role of anorectal and colonic function tests in constipation-predominant IBS remains unclear. The results of this study suggest that dyssynergic constipation can mimic IBS and that the identification and treatment of anorectal dyssynergia can improve IBS symptoms. Thus, constipation patients with IBS who have symptoms that interfere with their quality of life should undergo colonic and anorectal physiological tests similarly to constipation patients without IBS to determine the presence of anorectal dyssynergia.
The defecation index was not significantly different between the patients with and without IBS in our study. This finding suggests that anorectal dyssynergia is not the sole mechanism responsible for the development of IBS symptoms in our study. The results of our study implied that anorectal dyssynergia might unmask IBS symptoms in patients with subclinical IBS.
In this study, 60% of the patients reported a subjective improvement of their overall constipation symptoms. This result is similar to that reported in previous studies that used manometry [29] [30] [31] [32] [33] [34] [35] [36] or electromyography-based techniques. 17 We discovered 3 factors, a baseline constipation symptom score, colonic transit time, and rectal sensation, that could predict the treatment outcome. A high constipation symptom score that was associated with a poor treatment outcome may be explained by the high prevalence of impaired rectal sensation and delayed colonic transit in the patients with high symptom score. It is unclear whether impaired rectal sensation is the cause or the outcome of constipation. Previous studies have demonstrated trends toward lower rectal sensory thresholds after biofeedback therapy in patients with constipation. 37, 38 In our biofeedback treatment protocol, we did not perform rectal sensory training, which could explain the poor response observed in patients with increased rectal sensory thresholds. However, the benefit of rectal sensory training during biofeedback therapy on the treatment outcome remains controversial, because both benefits and no effect of sensory training on the treatment outcome have been reported. 33, 39 
CONCLUSIONS
In conclusion, this study suggests that the presence of IBS in dyssynergic constipation patients does not affect the outcome of the biofeedback therapy. Dyssynergic constipation patients with or without IBS will likely benefit from biofeedback therapy. Therefore, chronic constipation patients should undergo anorectal function tests to identify 
